Aurolab 房水引流植入物治疗成人难治性青光眼的长期结局
该回顾性病例系列纳入 282 例(282 眼)接受 Aurolab 房水引流植入物(AADI)手术且随访超过 5 年的难治性青光眼成人患者。眼压从基线 33.1±10.4 mmHg 降至 5 年时 16.5±6.5 mmHg,5 年累积失败概率为 34.4%(95%CI 29.2 至 40.3)。角膜内皮失代偿是最常见并发症(32 眼,11%)。
要点
- AADI 术后 5 年眼压由 33.1±10.4 mmHg 降至 16.5±6.5 mmHg,5 年累积失败概率 34.4%(95%CI 29.2 至 40.3)。
- 角膜内皮失代偿为最常见并发症,发生 32 眼(11%);迟发性低眼压仅 4 眼(1.4%)。
- 校正年龄、性别及既往小梁切除术后,继发性青光眼失败风险降低 32%(HR=0.68,95%CI 0.50 至 0.94,p=0.02)。
核心结论
- AADI 在成人难治性青光眼中 5 年内眼压控制良好,但角膜内皮失代偿仍是需关注的问题。
研究设计与样本
- 回顾性、非对照、干预性病例系列,纳入 2012 至 2018 年间接受 AADI 手术、年龄>18 岁且随访>5 年的患者。
- 共纳入 282 例患者 282 眼,平均年龄 45.2±12.3 岁,男性 191 例(68%)。
主要发现
- 眼压(均值±SD)从基线 33.1±10.4 mmHg 降至 5 年时 16.5±6.5 mmHg。
- 5 年累积失败概率为 34.4%(95%CI 29.2 至 40.3)。
- 角膜内皮失代偿发生于 32 眼(11%),迟发性低眼压仅 4 眼(1.4%)。
- 校正年龄、性别及既往小梁切除术后,继发性青光眼失败风险降低 32%(HR=0.68,95%CI 0.50 至 0.94,p=0.02)。
关键数值与推荐
- 失败定义为眼压>21 mmHg 或较基线下降<20%、眼压≤5 mmHg、因青光眼或并发症再手术、或光感丧失。
临床怎么用
- AADI 可作为成人难治性青光眼的一种可选引流植入物,术后需长期监测眼压及角膜内皮状况。
- 继发性青光眼患者使用 AADI 时失败风险相对更低。
局限性
- 回顾性、非对照设计,仅纳入随访超过 5 年的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report long-term outcomes of Aurolab aqueous drainage implant (AADI) surgery in adults with refractory glaucoma. DESIGN: Retrospective, non-comparative, interventional case series. METHODS: Case records of patients aged >18 years who underwent AADI surgery between 2012 and 2018 and had >5 years of follow-up were reviewed. Intraocular pressure (IOP), visual acuity, number of IOP-lowering medications, complications and reoperations were recorded at baseline and at 1 day, 1 month, 3 months, 6 months, 1 year and annually thereafter. Failure was defined as IOP>21 mmHg or reduced<20% below the baseline, IOP≤5 mmHg, reoperation for glaucoma or a complication or loss of light perception vision. RESULTS: The study included 282 eyes from 282 patients. Age (mean±SD) was 45.2±12.3 years, and 191 (68%) were men. Secondary angle closure glaucoma was the most common aetiologic group (30%), followed by secondary open angle glaucoma (25%) and primary open angle glaucoma (22%). IOP (mean±SD) decreased from 33.1±10.4 mmHg at baseline to 16.5±6.5 mmHg at 5 years. The cumulative probability of failure was 34.4% (95% CI 29.2 to 40.3) at 5 years. Corneal endothelial decompensation was the most common complication occurring in 32 eyes (11%). Delayed hypotony was seen in only four eyes (1.4%). After adjusting for age, sex and previous trabeculectomy, eyes with secondary glaucoma had a 32% lower risk of failure (HR=0.68, 95% CI 0.50 to 0.94, p=0.02). CONCLUSION: The AADI showed good control of IOP over 5 years, but corneal endothelial decompensation remains a concern.
引用
- Puthuran GV, Palmberg PF, Talla S, et al. Long-term outcomes of Aurolab aqueous drainage implant in adults with refractory glaucoma. Br J Ophthalmol. 2026. PMID: 41611470. doi:10.1136/bjo-2025-327124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。